Teva Pharmaceutical reported US$16.9 billion in full year revenue in its results for the year and the quarter ended December 31, 2019.
Teva Pharmaceutical Industries (NYSE:TEVA,TASE:TEVA) reported US$16.9 billion in full year revenue in its results for the year and the quarter ended December 31, 2019.
As quoted in the press release:
“In 2019, we made great strides towards positioning Teva for renewed growth by completing our two-year restructuring plan, reducing our cost base by more than $3 billion, and reducing our net debt by more than $9 billion, all while maintaining our global leadership in generics, serving around 200 million patients every day,” said Mr. Kåre Schultz, Teva’s President and CEO.
“Our key growth products met major milestones in 2019, including the launch of AJOVY® in Europe, continued strong growth for AUSTEDO®, and the successful launch of our first biosimilar TRUXIMA® in North America. In 2020, we expect to see continued growth for AJOVY®, AUSTEDO® and our biosimilars.”